**NM signifies a non meaningful value. A dash signifies the data is not available.

Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced only "mild to moderate" gastrointestinal side effects, says Novo, and in exchange enjoyed a 9.7% average ...

Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug, amycretin. Warning! GuruFocus has ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...